Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242, USA.
Circ Res. 2012 Nov 9;111(11):1446-58. doi: 10.1161/CIRCRESAHA.112.271577. Epub 2012 Sep 7.
RATIONALE: Activation of peroxisome proliferator-activated receptor-γ (PPARγ) by thiazolidinediones lowers blood pressure, whereas PPARγ mutations cause hypertension. Previous studies suggest these effects may be mediated through the vasculature, but the underlying mechanisms remain unclear. OBJECTIVE: To identify PPARγ mechanisms and transcriptional targets in vascular smooth muscle and their role in regulating resistance artery tone. METHODS AND RESULTS: We studied mesenteric artery (MA) from transgenic mice expressing dominant-negative (DN) mutant PPARγ driven by a smooth muscle cell-specific promoter. MA from transgenic mice exhibited a robust increase in myogenic tone. Patch clamp analysis revealed a reduced large conductance Ca(2+)-activated K(+) (BKCa) current in freshly dissociated smooth muscle cell from transgenic MA. Inhibition of protein kinase C corrected both enhanced myogenic constriction and impaired the large conductance Ca(2+)-activated K(+) channel function. Gene expression profiling revealed a marked loss of the regulator of G protein signaling 5 (RGS5) mRNA in transgenic MA, which was accompanied by a substantial increase in angiotensin II-induced constriction in MA. Small interfering RNA targeting RGS5 caused augmented myogenic tone in intact mesenteric arteries and increased activation of protein kinase C in smooth muscle cell cultures. PPARγ and PPARδ each bind to a PPAR response element close to the RGS5 promoter. RGS5 expression in nontransgenic MA was induced after activation of either PPARγ or PPARδ, an effect that was markedly blunted by DN PPARγ. CONCLUSIONS: We conclude that RGS5 in smooth muscle is a PPARγ and PPARδ target, which when activated blunts angiotensin II-mediated activation of protein kinase C, and preserves the large conductance Ca(2+)-activated K(+) channel activity, thus providing tight control of myogenic tone in the microcirculation.
原理:噻唑烷二酮类药物激活过氧化物酶体增殖物激活受体-γ(PPARγ)可降低血压,而 PPARγ 突变会导致高血压。先前的研究表明,这些作用可能是通过血管介导的,但潜在的机制尚不清楚。
目的:确定血管平滑肌中 PPARγ 的机制和转录靶标及其在调节阻力动脉张力中的作用。
方法和结果:我们研究了表达由平滑肌细胞特异性启动子驱动的显性负(DN)突变 PPARγ 的转基因小鼠的肠系膜动脉(MA)。转基因小鼠的 MA 表现出强烈的肌源性张力增加。膜片钳分析显示,从转基因 MA 分离的平滑肌细胞中的大电导钙激活钾(BKCa)电流减少。蛋白激酶 C 抑制纠正了增强的肌源性收缩和受损的大电导钙激活钾通道功能。基因表达谱分析显示,转基因 MA 中的 G 蛋白信号调节因子 5(RGS5)mRNA 明显丢失,同时血管紧张素 II 诱导的 MA 收缩显著增加。靶向 RGS5 的小干扰 RNA 导致完整肠系膜动脉的肌源性张力增加,并增加平滑肌细胞培养物中的蛋白激酶 C 激活。PPARγ 和 PPARδ 都与靠近 RGS5 启动子的 PPAR 反应元件结合。非转基因 MA 中的 RGS5 表达在激活 PPARγ 或 PPARδ 后被诱导,该作用在 DN PPARγ 存在下明显减弱。
结论:我们得出结论,平滑肌中的 RGS5 是 PPARγ 和 PPARδ 的靶标,当被激活时,它可减弱血管紧张素 II 介导的蛋白激酶 C 激活,并保留大电导钙激活钾通道的活性,从而在微循环中对肌源性张力进行严格控制。
Arterioscler Thromb Vasc Biol. 2015-8
Arterioscler Thromb Vasc Biol. 2015-12-10
Biochem Pharmacol. 2023-12
Int J Mol Sci. 2023-1-10
Front Physiol. 2021-12-13
Circ Res. 2021-4-2
Curr Hypertens Rep. 2020-8-27
Diabetes Ther. 2012-2-29
Proc Natl Acad Sci U S A. 2010-4-12
Arterioscler Thromb Vasc Biol. 2009-12-17